Mediwound Stock News

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Announces Publication Of Positive Late-Stage Data For Keytruda-Chemo Combo In Breast Cancer Merc

MediWound (MDWD) is trading ~7% higher in the pre-market on Thursday after announcing that the Biomedical Advanced Research and Development Authority ((BARDA)) provided the company with

Primary Endpoint Met with Highly Statistically Significant ResultsNo Observed Safety IssuesFinal Data Readout Expected in Second Quarter of 2022

MediWound Ltd (NASDAQ: MDWD) has posted topline results from its U.S. Phase 2 study of EscharEx for the debridement (removal of dead or infected skin tissue for wound healing) of venous leg ulcers

In a phase two study, EscharEx demonstrated safe and effective debridement of diabetic foot ulcers and venous leg ulcers.

Wall Street analysts expect MediWound Ltd. (NASDAQ:MDWD) to report $5.65 million in sales for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for MediWounds earnings. The lowest sales estimate is $5.60 million and the highest is $5.70 million. MediWound reported sales of $6.67 million during the same quarter last year, which []

Analysts predict that MediWound Ltd. (NASDAQ:MDWD) will announce earnings per share of ($0.16) for the current quarter, Zacks reports. Two analysts have made estimates for MediWound’s earnings, with the highest EPS estimate coming in at ($0.14) and the lowest estimate coming in at ($0.17). MediWound reported earnings per share of ($0.06) during the same quarter […]

Topline Data Expected in the First Quarter of 2022 Topline Data Expected in the First Quarter of 2022

Topline Data Expected in the First Quarter of 2022 Topline Data Expected in the First Quarter of 2022

Equities research analysts expect that MediWound Ltd. (NASDAQ:MDWD) will announce sales of $5.65 million for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for MediWounds earnings, with estimates ranging from $5.60 million to $5.70 million. MediWound reported sales of $6.67 million in the same quarter last year, which would indicate a []

MediWound Ltd. (NASDAQ:MDWD) was the recipient of a significant drop in short interest during the month of November. As of November 15th, there was short interest totalling 323,800 shares, a drop of 20.7% from the October 31st total of 408,500 shares. Based on an average daily volume of 100,300 shares, the short-interest ratio is currently []

Squarepoint Ops LLC acquired a new stake in MediWound Ltd. (NASDAQ:MDWD) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 17,009 shares of the biopharmaceutical companys stock, valued at approximately $65,000. Squarepoint Ops LLC owned approximately 0.06% of MediWound as of []

MediWound Ltd. (NASDAQ:MDWD) Equities research analysts at Oppenheimer cut their FY2021 earnings per share (EPS) estimates for MediWound in a research note issued on Tuesday, November 16th. Oppenheimer analyst K. Degeeter now expects that the biopharmaceutical company will earn ($0.48) per share for the year, down from their previous estimate of ($0.46). Oppenheimer also []

Anticipate Submission for Label Extension in First Half 2022 Anticipate Submission for Label Extension in First Half 2022

MediWound (NASDAQ:MDWD) issued its quarterly earnings results on Monday. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, topping the Thomson Reuters consensus estimate of ($0.13) by $0.01, MarketWatch Earnings reports. MediWound had a negative return on equity of 171.14% and a negative net margin of 38.43%. During the same quarter last []